To investigate the effects of Guizhi Fuling capsule on bone mineral density(BMD), transforming growth factor(TGF)-β, prostaglandin(PG) F2α and antiendometrium antibody(EMAb) in endometriosis(EMT) patients with Qi stagnation and blood stasis syndrome after surgery.
A total of 169 EMT patients with Qi stagnation and blood stasis syndrome who underwent laparoscopic ectopic lesion resection in Baoding First Central Hospital from January 2022 to December 2024 were selected and randomly divided into the observation group(85 cases) and the control group(84 cases). After surgery, both groups were treated with dydrogesterone. The control group was additionally given leuprorelin acetate, while the observation group was additionally treated with Guizhi Fuling capsule. The clinical efficacy, BMD, TGF-β, PGF2α, EMAb, sex hormones, cyst diameter, Endometriosis Health Profile(EHP)-30 score, adverse events and recurrence rate were compared between the two groups.
The total effective rate of the observation group was higher than that of the control group(94.12% vs. 84.52%), with a significant difference(P<0.05). After treatment, the BMD of lumbar spine and femoral trochanter in the observation group were higher than those in the control group, the levels of TGF-β, PGF2α, EMAb, luteinizing hormone, estradiol, follicle-stimulating hormone, as well as cyst diameter and EHP-30 score in both groups were lower than those before treatment, and the above indicators in the observation group were lower than those in the control group. All the above differences were statistically significant(P<0.05). There was no significant difference in the incidence of postoperative adverse events between the two groups(P>0.05), while the recurrence rate of the observation group was lower than that of the control group(P<0.05).
For EMT patients with Qi stagnation and blood stasis syndrome, the intervention of Guizhi Fuling capsule after laparoscopic lesion resection achieves ideal clinical efficacy. It can effectively improve postoperative symptoms and BMD, regulate the abnormal expression of serum TGF-β, PGF2α and EMAb, and reduce the postoperative recurrence risk of the disease.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |